Complement activation profiles in anti-acetylcholine receptor positive myasthenia gravis.
Humans
Autoantibodies
/ immunology
Case-Control Studies
Complement Activation
/ immunology
Complement System Proteins
/ analysis
Myasthenia Gravis
/ classification
Receptors, Cholinergic
/ immunology
Complement Pathway, Alternative
Complement Pathway, Classical
Male
Female
Young Adult
Adult
Middle Aged
acetylcholine receptor
antibodies
biomarker
complement activation
myasthenia gravis
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
revised:
24
10
2022
received:
01
09
2022
accepted:
02
02
2023
medline:
6
4
2023
pubmed:
9
2
2023
entrez:
8
2
2023
Statut:
ppublish
Résumé
Complement component 5 (C5) targeting therapies are clinically beneficial in patients with acetylcholine receptor antibody In a case-control study, concentrations of C3a, C5a and sC5b9 were simultaneously quantified, indicating general activation of the complement system, whether via the classical and lectin pathways (C4a) or the alternative pathway (factors Ba and Bb) in MG patients with AChR or muscle-specific kinase antibodies (MuSK-Abs) or seronegative MG compared to healthy donors. Treatment-naïve patients with AChR-Ab Markers indicative of complement activation are prominently increased in patients with AChR-Ab MG despite standard immunosuppressive therapies. Complement inhibition proximal to C5 cleavage should be explored for its potential therapeutic benefits in AChR-Ab
Sections du résumé
BACKGROUND AND PURPOSE
Complement component 5 (C5) targeting therapies are clinically beneficial in patients with acetylcholine receptor antibody
METHODS
In a case-control study, concentrations of C3a, C5a and sC5b9 were simultaneously quantified, indicating general activation of the complement system, whether via the classical and lectin pathways (C4a) or the alternative pathway (factors Ba and Bb) in MG patients with AChR or muscle-specific kinase antibodies (MuSK-Abs) or seronegative MG compared to healthy donors.
RESULTS
Treatment-naïve patients with AChR-Ab
CONCLUSIONS
Markers indicative of complement activation are prominently increased in patients with AChR-Ab MG despite standard immunosuppressive therapies. Complement inhibition proximal to C5 cleavage should be explored for its potential therapeutic benefits in AChR-Ab
Substances chimiques
Autoantibodies
0
Complement System Proteins
9007-36-7
Receptors, Cholinergic
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1409-1416Informations de copyright
© 2023 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.